Investigation of Cardiovascular Effects of Tetrahydro-β-carboline sstr3 antagonists

[Image: see text] Antagonism of somatostatin subtype receptor 3 (sstr3) has emerged as a potential treatment of Type 2 diabetes. Unfortunately, the development of our first preclinical candidate, MK-4256, was discontinued due to a dose-dependent QTc (QT interval corrected for heart rate) prolongatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: He, Shuwen, Lai, Zhong, Ye, Zhixiong, Dobbelaar, Peter H., Shah, Shrenik K., Truong, Quang, Du, Wu, Guo, Liangqin, Liu, Jian, Jian, Tianying, Qi, Hongbo, Bakshi, Raman K., Hong, Qingmei, Dellureficio, James, Reibarkh, Mikhail, Samuel, Koppara, Reddy, Vijay B., Mitelman, Stan, Tong, Sharon X., Chicchi, Gary G., Tsao, Kwei-Lan, Trusca, Dorina, Wu, Margaret, Shao, Qing, Trujillo, Maria E., Fernandez, Guillermo, Nelson, Donald, Bunting, Patricia, Kerr, Janet, Fitzgerald, Patrick, Morissette, Pierre, Volksdorf, Sylvia, Eiermann, George J., Li, Cai, Zhang, Bei, Howard, Andrew D., Zhou, Yun-Ping, Nargund, Ravi P., Hagmann, William K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2014
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4094257/
https://ncbi.nlm.nih.gov/pubmed/25050159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml500028c
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados